Baxter International

“We see the May data as proving continued support for an important element of our bullish thesis on Baxter International Inc. (NYSE: BAX),” Piper Jaffray wrote in a report this morning. “IVIG growth will remain stable over the intermediate and long term. After a tumultuous 1Q10 last year driven...

Goldman Sachs has changed the price targets on the following companies: Affymetrix (NASDAQ: AFFX) from $4.50 to $5, Sell Bank of New York Mellon (NYSE: BK) from $30 to $29, Neutral Baxter International (NYSE: BAX) from $69 to $72, Buy CME Group (NASDAQ: CME) from $345 to $325, Neutral...

Morgan Keegan has raised the price target on Baxter International (NYSE: BAX) from $64 to $70 and maintains its Outperform rating.

Bank of America has raised the price objective on Baxter International (NYSE: BAX) to $67 and maintains its Buy rating.

Piper Jaffray is reiterating its OW rating on shares of Baxter International Inc. (NYSE: BAX). “The consent agreement with the FTC requiring the sale of a portion of Talecris' assets is not so unexpected and could create an opportunity for Baxter and other competitors like CSL,” Piper Jaffray...

According to Piper Jaffray, Baxter International (NYSE: BAX) Q1 results were strong across the board with a solid beat in the company's Bioscience (+$68MM) and Medication Delivery (+$73MM). Piper Jaffray said that within the segments, the Bioscience beat was driven by the key franchises of...

Piper Jaffray is maintaining its OW rating on shares of Baxter International Inc. (NYSE: BAX). “Adjusted ‘apples-to-apples' US IVIG distributions improved again in February, up 10% vs. the prior year,” Piper Jaffray writes. “Growth among major players continues to be driven by share gains...

In a report published by J.P. Morgan, Baxter Intl (NYSE: BAX) presented HyQ at AAAAI. J.P. Morgan said that Baxter has licensed hyaluronidase from Halozyme for use in SubQ IG. The company's Phase III, open label study (n=89 at 15 centers in U.S. and Canada) completed follow up in December 2010 and...

In a report published by Morgan Keegan, Baxter International (NYSE: BAX) saw an FDA safety alert on CSL's Vivaglobin, but it should present minimal risk to HyQ. Morgan Keegan said that, on Friday, the FDA issued a safety communication regarding postmarketing reports suggesting the risk of serious...

Piper Jaffray has published a research report on Baxter International (NYSE: BAX) after the company report strong October data and the Octapharma line was recalled. In the report, Piper Jaffray writes "US monthly IVIG distributions were up 6% in October (up 16% adjusting for the Octapharma recall...

Morgan Keegan is responding to the investor questions it received regarding the Sigma pump recall. “Sigma is repairing spectrum pumps and not offering loaner units on the 17,568 units under the recall,” Morgan Keegan writes. “As such, Sigma's ability to manufacture new pumps for Baxter should not...

This morning, Deutsche Bank is commenting on Baxter International Inc. (NYSE: BAX), which it said has had a nice move from the low $40s into the $50s on the back of the Octapharma recall and better results. “We think there's still upside left into the mid-$50s given the stock's current valuation...

JP Morgan has issued a research report on Baxter International (NYSE: BAX) to reflect the weakness compared to the Euro and the Yen. In the report, JP Morgan writes "For 2010, we forecast revenue of $13.03B (+3.7%, +2.1% constant currency) and EPS of $3.98 (+4.8%), which is at the top end of...

Morgan Keegan has published a research report for Baxter International Inc. (NYSE: BAX) and has reiterated its Outperform rating. In the report, Morgan Keegan writes "Preliminary phase III data for Baxter's Hy-Q subcutaneous IVIG will be presented on October 6th at the European Society for...

Goldman Sachs has published a research report for Baxter International Inc. (NYSE: BAX). In the report, Goldman writes "We attended Biogen Idec's Hemophilia R&D Roundtable in Cambridge, MA, to get an update on the Hemophilia market as well as new recombinant technologies. We came away...